Zydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized through a subsidiary, makes Assertio a wholly-owned entity, bolstering Zydus's specialty and oncology supportive-care therapies pipeline. This strategic move aims to enhance the company's innovative drug offerings.
Zydus Lifesciences' shares experienced a 2% dip after the completion of its $166.4 million acquisition of US-based Assertio Holdings Inc. This strategic deal, finalized through a subsidiary, integrates Assertio as a wholly-owned entity, significantly bolstering Zydus's specialty…
Market Samachar is a news aggregator. This article was originally published by Stocks-Markets-Economic Times. Tap the button above to read the full story on their site.